Octreotide Global Market Report 2025

The octreotide market size has grown strongly in recent years. It will grow from $2.45 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the rising prevalence of acromegaly and hormonal disorders, greater awareness of early diagnosis, the expansion of healthcare infrastructure, and an increase in cancer diagnoses.

The octreotide market size is expected to see strong growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the increasing geriatric population, rising awareness and early diagnosis, a higher occurrence of severe diarrhea, growing healthcare spending, and an expanding pipeline of drugs. Key trends include advanced drug launches, new product introductions, regulatory approvals, technological innovations, and expansion into emerging markets.

The rising incidence of cancer is expected to drive the growth of the octreotide market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The increase in cancer cases is primarily attributed to aging populations, environmental influences, lifestyle factors, and advancements in detection methods. Octreotide plays a crucial role in addressing the growing cancer burden by inhibiting tumor growth, managing hormone-related cancers, and alleviating associated symptoms. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide. Projections for 2040 indicate an increase to 29.9 million cases and 15.3 million deaths. As a result, the rising cancer rates are fueling the expansion of the octreotide market.

Leading companies in the octreotide market are prioritizing the development of innovative products, such as injectable suspensions, to enhance patient adherence and convenience. These injectable suspensions are fast-acting medications administered via injection, ensuring quicker absorption into the bloodstream while bypassing the digestive system for a faster onset of action. For instance, in October 2024, Teva Pharmaceuticals, an Israel-based pharmaceutical company, introduced a generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension). This injectable formulation is designed for rapid absorption, offering an effective alternative to oral medications. Octreotide, a synthetic analog of the natural hormone somatostatin, is widely used to treat conditions such as acromegaly, carcinoid syndrome, and VIP-secreting tumors. The injectable delivery method ensures a faster onset of action, improving treatment adherence for patients.

In April 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical company, acquired Amryt Pharma Plc for an undisclosed sum. This strategic acquisition expands Chiesi’s presence in the rare disease sector, strengthening its ability to provide innovative treatments. The deal further supports Chiesi’s commitment to improving patient access to transformative therapies for rare and complex conditions. Amryt Pharma Plc, an Ireland-based biopharmaceutical company, specializes in the development and commercialization of octreotide-based treatments for rare and orphan diseases.

Major players in the octreotide market are Novartis International AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Bachem Holding AG, Chemi S.p.A., LGM Pharma LLC, Hainan Shuangcheng Pharmaceuticals Co. Ltd., USV Private Limited, ChemWerth Inc., Shanghai Soho-Yiming Pharmaceuticals Co. Ltd., Neiss Labs Private Limited, Samarth Life Sciences Private Limited, TAPI Technology & API Services, and BCN Peptides S.A.

North America was the largest region in the octreotide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in octreotide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the octreotide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Octreotide is a synthetic somatostatin analog used to treat various medical conditions by inhibiting hormone secretion. Available in both short-acting and long-acting formulations, it helps manage hormone-related disorders but may lead to side effects such as gastrointestinal issues and gallstones.

The primary types of octreotide include octreotide acetate, octreotide, octreotide chloride, octreotide hydrochloride, and indium in-111 octreotide. Octreotide acetate is a synthetic somatostatin analog used to treat hormone-secreting tumors, acromegaly, and severe diarrhea associated with certain cancers. These variants are available in multiple forms, including injections, powders, and microspheres, and are prescribed for conditions such as diarrhea, acromegaly, and other related disorders. Octreotide is distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with end users primarily in the pharmaceutical and clinical research sectors.

The octreotide market research report is one of a series of new reports that provides octreotide market statistics, including the octreotide industry global market size, regional shares, competitors with the octreotide market share, detailed octreotide market segments, market trends, and opportunities, and any further data you may need to thrive in the octreotide industry. This octreotide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The octreotide market consists of sales of short-acting octreotide formulations, long-acting octreotide formulations, and other extended-release formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.